Tirzepatide ODT 3mg

Tirzepatide ODT 3 mg is a compounded orally disintegrating formulation of tirzepatide designed as a needle-free alternative to injectable therapy. Tirzepatide functions as a dual incretin agonist, targeting both GLP-1 and GIP receptors to improve glycemic control, enhance insulin secretion, suppress glucagon release, and reduce appetite. These combined mechanisms contribute to significant weight loss and improved metabolic outcomes in patients with obesity or type 2 diabetes. The ODT version is intended to dissolve in the mouth for transmucosal absorption, typically administered once daily. However, unlike FDA-approved injectable formulations, compounded tirzepatide ODT has not undergone the same rigorous clinical trials, and its bioavailability may be variable. As a result, dosing is not directly equivalent to injectable forms, and clinical response can differ between patients. Common side effects mirror those of GLP-1 receptor agonists and include nausea, decreased appetite, constipation, and fatigue. Despite its convenience, use of tirzepatide ODT should be guided by a qualified healthcare provider due to variability in absorption and limited long-term safety data. Citation: U.S. Food and Drug Administration; New England Journal of Medicine